secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274318
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports Q3 2025 net loss of $26.0M; cash $174M into late 2026
--------------------------------------------------------------------------------

- Net loss $26.0M ($0.35/sh) vs $15.1M ($0.21) in Q3 2024; R&D spend $20.3M up 69% YoY.
- Cash $174M as of Sep 30, 2025, down from $227M at Dec 31, 2024; runway into late 2026.
- Clinical: VMT-α-NET cohort 3 opened June 2025, 8 patients enrolled; favorable safety in 55 patients.
- VMT01 melanoma: 5 patients dosed at 3.0 mCi (monotherapy or +nivolumab) as of Oct 31, 2025.
- PSV359 FAP-α therapy: 3 patients treated as of Oct 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312525274318/0001193125-25-274318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312525274318/catx-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer